2024 Exhibitors Search
Astrion Co., Ltd.
| Country | Korea, South |
|---|---|
| Address | |
| Tel (Rep.) | 02-921-7111 |
| Website | http://www.astrion.co.kr |
Company Introduction
We are conducting research and development with the goal of developing a small molecule brain tumor treatment that simultaneously targets new brain tumor targets with our main pipeline, “AON-MG23”, and with the goal of developing a treatment for Parkinson’s disease with “AON-PP23”. Currently, "AON-MG23" has proven its excellent effectiveness in animal transplant models and the drug combination effect has also been confirmed. Currently, it has entered the non-clinical stage and is pursuing research to expand indications by confirming the drug's efficacy in triple-negative breast cancer and lung cancer, with the goal of receiving clinical trial approval from the FDA within 2025.
Promotional video
Exhibit Item
Development of candidate for incurable anticancer drugs such as glioblastoma and triple-negative breast and lung cancer
Exhibit Description
1) AON-MG23: A small molecule compound-based glioblastoma treatment that decomposes the functional complex between ANO1 and EGFR.
2) AON-MH23, AON-MB23, AON-ML23: Head and neck cancer, triple negative breast cancer, and non-small cell lung cancer treatment developed by expanding the indications of AON-MG23
2) AON-MH23, AON-MB23, AON-ML23: Head and neck cancer, triple negative breast cancer, and non-small cell lung cancer treatment developed by expanding the indications of AON-MG23
Co-Exhibitor or Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.